0
Original Research: ASTHMA |

Bronchodilator Effect of Infused B-Type Natriuretic Peptide in Asthma*

Michael J. Akerman, MD; Makito Yaegashi, MD; Zothanmawii Khiangte, MD; Anandhi T. Murugan, MD; Olumayowa Abe, MD; Jonathan D. Marmur, MD
Author and Funding Information

Affiliations: *From the Divisions of Pulmonary and Critical Care Medicine (Drs. Akerman, Yaegashi, and Khiangte) and Cardiology (Dr. Marmur), and the Department of Medicine (Drs. Murugan and Abe), State University of New York, Health Science Center at Brooklyn, Brooklyn, NY.,  Dr. Akerman and Dr. Yaegashi contributed equally to this work.,  Dr. Yaegashi is currently located at the Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

Correspondence to: Michael J. Akerman, MD, Division of Pulmonary and Critical Care Medicine, State University of New York, Health Science Center at Brooklyn, 450 Clarkson Ave, Box 19, Brooklyn, NY 11203; e-mail: Michael.akerman@downstate.edu



Chest. 2006;130(1):66-72. doi:10.1378/chest.130.1.66
Text Size: A A A
Published online

Study objective: To determine the bronchodilator effect of recombinant human B-type natriuretic peptide (BNP; nesiritide) on patients with asthma.

Design: A prospective, open-label study.

Setting: Outpatient setting.

Patients: Eight adult patients with asthma confirmed by > 12% and > 200 mL increase in FEV1 after bronchodilator inhalation.

Interventions: An IV nesiritide bolus, 2 μg/kg, followed by continuous infusion for a total of 3 h at escalating doses of 0.01, 0.02, and 0.03 μg/kg/min for 1 h each as tolerated.

Measurements: Spirometry and forced oscillation technique (FOT) measurements were both obtained at baseline and every 30 min during the infusion. Two doses of albuterol, 90 μg, inhalation via metered-dose inhaler were then administered at the end of nesiritide infusion, followed by repeat spirometry and FOT measurements after 30 min. Primary end points were FEV1 and FVC changes after the nesiritide infusion for 3 h. Wilcoxon signed-ranks tests were used to compare the effects of nesiritide and albuterol.

Results: Baseline measurements (mean ± SD) were as follows: FEV1, 1.89 ± 0.87 L; FVC, 3.02 ± 0.99 L; respiratory resistance at 5 Hz (Rrs5), 10.3 ± 3.85 cm H2O · s/L; and mean respiratory resistance at 5 to 20 Hz, 7.56 ± 1.92 cm H2O/L/s. Mean baseline serum BNP level was 27 ± 27 pg/mL. After 180 min of nesiritide infusion, the following measurements showed significant changes: FEV1 increased to 2.41 ± 0.78 L (mean increase, 520 mL), p = 0.012; FVC increased to 3.65 ± 1.05 L (mean increase, 630 mL), p = 0.017; and Rrs5 decreased to 8.24 ± 4.02 cm H2O/L/s, p = 0.017. After albuterol, there were no further significant changes in these measurements.

Conclusion: IV nesiritide is an effective bronchodilator in patients with asthma.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543